GlycoMimetics Stock Quote GLYC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.2499

Bid

0.2499

Ask

0.25

Volume

4,735,592

0.2022 Day's Range 0.2546

0.2022 52 Week Range 3.5299

Market Cap

16.11M

Previous Close

0.3103

Open

0.2455

Last Trade

281

0.2499

Last Trade Time

11:59:18

Financial Volume

$ 1,101,481

VWAP

0.232596

Average Volume (3m)

4,757,825

Shares Outstanding

64,464,412

Dividend Yield

PE Ratio

-0.40

Earnings Per Share (EPS)

-0.57

Revenue

10k

Net Profit

-36.9M

GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbo... GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.glycomimetics.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

GlycoMimetics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GLYC. The last closing price for GlycoMimetics was $0.31. Over the last year, GlycoMimetics shares have traded in a share price range of $ 0.2022 to $ 3.5299.

GlycoMimetics currently has 64,464,412 shares outstanding. The market capitalization of GlycoMimetics is $20 million. GlycoMimetics has a price to earnings ratio (PE ratio) of -0.40.

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

After meeting with the U.S. Food and Drug Administration (FDA), it has been determined that the regulatory path forward for uproleselan in relapsed and refractory (R/R) Acute Myeloid Leukemia...

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Form 8-K - Current report

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant...

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Adverse events were consistent with known side effect...

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0575	-18.7052700065	0.3074	0.33	0.2022	832799	0.31305058	CS
4	-0.0251	-9.12727272727	0.275	0.33	0.2022	1230151	0.29807762	CS
12	-1.4301	-85.125	1.68	1.84	0.2022	4757825	0.32219335	CS
26	-2.8201	-91.8599348534	3.07	3.5	0.2022	2418558	0.56565754	CS
52	-1.4001	-84.8545454545	1.65	3.5299	0.2022	1286749	0.67446864	CS
156	-1.8501	-88.1	2.1	4.16	0.2022	734205	1.21615941	CS
260	-8.8501	-97.2538461538	9.1	9.53	0.2022	684084	2.00584697	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
POAIPredictive Oncology Inc	$ 1.9233 (79.75%)	133.02M
PBMPsyence Biomedical Ltd	$ 0.64468 (64.71%)	64.99M
SLRXSalarius Pharmaceuticals Inc	$ 3.36 (57.01%)	22.26M
XCURExicure Inc	$ 0.5502 (37.93%)	23.14M
VKTXViking Therapeutics Inc	$ 69.39 (37.65%)	11.15M
TWOU2U Inc	$ 1.66 (-59.71%)	3.82M
CTNTCheetah Net Supply Chain Service Inc	$ 0.2888 (-40.08%)	6.68M
KDLYKindly MD Inc	$ 2.01 (-37.58%)	603.29k
EZFLEzFill Holdings Inc	$ 4.01 (-35.58%)	114.83k
SLGLSol Gel Technologies Ltd	$ 0.45 (-32.84%)	13.19M
NVDANVIDIA Corporation	$ 114.33 (0.07%)	272.68M
SQQQProShares UltraPro Short QQQ	$ 9.0701 (0.11%)	148.43M
SLNASelina Hospitality PLC	$ 0.0415 (-9.19%)	145.52M
POAIPredictive Oncology Inc	$ 1.925 (79.91%)	144.54M
PBMPsyence Biomedical Ltd	$ 0.64468 (64.71%)	70.49M